Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:43:15 EDT Sun 31 May 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-05-31 12:03U:IHNews ReleaseiHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
2026-05-31 10:18U:CPNews ReleaseCPKC to maintain rail operations across Canada during IBEW strike
2026-05-31 10:18U:CPNews ReleaseCPKC to maintain rail operations across Canada during IBEW strike
2026-05-31 09:06U:SMMTNews ReleaseIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
2026-05-31 09:00U:IMTXNews ReleaseImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
2026-05-31 08:30U:TEMNews ReleaseTempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
2026-05-31 08:29U:JNJNews ReleaseRYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
2026-05-31 08:15U:JNJNews ReleaseJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA(TM) (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
2026-05-31 08:06U:RVMDNews ReleaseRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2026-05-31 08:00U:REPLNews ReleaseReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
2026-05-31 08:00U:PFENews ReleasePfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
2026-05-31 08:00U:LLYNews ReleaseLilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
2026-05-31 08:00U:IMCRNews ReleaseImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
2026-05-31 08:00U:GRALNews ReleaseGRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri(TM) Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
2026-05-31 07:00U:SMXWNews ReleaseSMX and the Age of Parity: Certified Recycling Becomes the New Economics of Plastic
2026-05-31 07:00U:SMXNews ReleaseSMX and the Age of Parity: Certified Recycling Becomes the New Economics of Plastic
2026-05-30 22:45U:ELEKNews ReleaseAs Global Markets Discover Elektros, Microcap and Penny Stock Investors Are Beginning To Take Notice of a Growing EV Patent Technology and Lithium Mining Company
2026-05-30 22:15U:FUNNews ReleaseSIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD'S LONGEST FAMILY LAUNCH ROLLER COASTER
2026-05-30 22:00U:ELEKNews ReleaseGlobal EV Charging Patent Update: Elektros Inc. Continues To Advance and Protect Its Intellectual Property as EV Infrastructure Opportunities Expand Worldwide
2026-05-30 21:15U:ELEKNews ReleaseGlobal Microcap Investors Are Discovering a Rare Diamond in the Rough
2026-05-30 20:42U:AUMMFNews ReleaseResults of Annual General Meeting
2026-05-30 17:24U:BAYZFNews ReleaseASCO 2026: Bayer Shares New Findings for NUBEQA(TM) (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
2026-05-30 17:24U:BAYRYNews ReleaseASCO 2026: Bayer Shares New Findings for NUBEQA(TM) (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
2026-05-30 14:30U:WHWKNews ReleaseWhitehawk Therapeutics Presents Real-World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
2026-05-30 14:30U:PGENNews ReleasePrecigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
2026-05-30 14:30U:EIKNNews ReleaseEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
2026-05-30 14:15U:BNTXNews ReleaseGlobal Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial